TMEM65: A Potential Drug Target and Biomarker for Chronic Pain Management

Target Name: TMEM65

NCBI ID: G157378

TMEM65

Other Name(s): transmembrane protein 65 | hypothetical protein LOC286052 | LOC286052 | Transmembrane protein 65 | TMM65_HUMAN

TMEM65: A Potential Drug Target and Biomarker for Chronic Pain Management

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 57% of the global population experiences chronic pain, with 30% of these individuals having severe chronic pain that significantly affects their daily life. Chronic pain can be caused by various conditions, including musculoskeletal disorders, neuropathies, and inflammatory diseases. As an emerging field in pain management, the development of new treatments and biomarkers for chronic pain remains a major focus. In this article, we will explore TMEM65, a transmembrane protein 65 that has potential as a drug target and biomarker for chronic pain management.

TMEM65: Structure and Function

TMEM65 is a 21-kDa protein that belongs to the superfamily of transmembrane protein (SMT) family 65. TMEM65 is expressed in various tissues, including brain, spinal cord, and peripheral tissues, and has been shown to participate in various physiological processes, including cell signaling, neurotransmitter release, and pain perception.

TMEM65 is localized to the endoplasmic reticulum (ER) and transmembrane of the endoplasmic reticulum (ER) and has been shown to interact with various intracellular signaling pathways, including TGF-β, NF-kappa-B, and MAPK signaling pathways. TMEM65 has been shown to play a role in modulating pain perception and neuroinflammation.

TMEM65 has also been shown to be involved in the regulation of neurotransmitter release, including the release of GABA, a neurotransmitter that has anti-inflammatory properties. TMEM65 has been shown to interact with GABA receptors, which regulates the release of GABA and its effects on pain perception.

TMEM65 has been shown to participate in pain perception and neuroinflammation, making it a potential drug target for chronic pain management.

Drug Target Potential

TMEM65 has been shown to have potential as a drug target for chronic pain management due to its involvement in pain perception and neuroinflammation. Activation of the TGF-β pathway has been shown to contribute to pain perception and neuroinflammation. TMEM65 has been shown to regulate the TGF-β pathway, which can lead to decreased pain perception and improved neuroinflammation.

Furthermore, TMEM65 has been shown to play a role in the regulation of neurotransmitter release, including the release of GABA. The release of GABA is known to regulate pain perception and have anti-inflammatory effects. Therefore, inhibition of GABA release by TMEM65 could be a potential strategy for treating chronic pain.

Biomarker Potential

TMEM65 has also been shown to be involved in the regulation of pain perception and neuroinflammation, making it a potential biomarker for chronic pain. The levels of TMEM65 have been shown to be elevated in individuals with chronic pain, indicating that it may be a useful biomarker for the diagnosis and monitoring of chronic pain.

TMEM65 has been shown to have potential as a drug target for chronic pain management due to its involvement in pain perception and neuroinflammation. Further research is needed to fully understand TMEM65's role in chronic pain management and to develop effective treatments based on its potential as a drug target.

Conclusion

TMEM65 is a transmembrane protein that has potential as a drug target for chronic pain management due to its involvement in pain perception and neuroinflammation. Further research is needed to fully understand TMEM65's role in chronic pain management and to develop effective treatments based on its potential as a drug target. If proven to be effective, TMEM65 may provide a new treatment option for managing chronic pain.

Protein Name: Transmembrane Protein 65

Functions: May play an important role in cardiac development and function. May regulate cardiac conduction and the function of the gap junction protein GJA1. May contribute to the stability and proper localization of GJA1 to cardiac intercalated disk thereby regulating gap junction communication (By similarity). May also play a role in the regulation of mitochondrial respiration and mitochondrial DNA copy number maintenance (PubMed:28295037)

The "TMEM65 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM65 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets